Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme
Open Access
- 15 August 2002
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 16 (8) , 1431-1442
- https://doi.org/10.1046/j.1365-2036.2002.01285.x
Abstract
Background : Helicobacter pylori infection has been proposed as a protective factor against the development of gastro‐oesophageal reflux disease. Aim : To study heartburn and endoscopic findings before and after H. pylori eradication therapy in patients with peptic ulcer disease. Methods : In a multicentre trial programme, patients (n = 1497) were randomized to the omeprazole triple therapy group or to the control group, and were followed for 1–6 months after treatment. Patients in whom the infection was eradicated were compared with those in whom infection persisted. The severity of heartburn was measured at baseline and at each return visit. Endoscopy was performed 6 months after therapy in two of the five studies. Results : In patients with duodenal ulcer, there was a significantly lower prevalence of heartburn after successful eradication of H. pylori relative to that after failed eradication (estimated odds ratio, 0.48). The reduction in the prevalence of heartburn in patients with gastric ulcer was independent of the post‐treatment H. pylori status. In studies in which ulcer relapse was included in the model, this factor emerged as a significant factor for heartburn. The observed incidence of oesophagitis at the last visit was not influenced by H. pylori status. Conclusions : Eradication of H. pylori in patients with peptic ulcer disease was associated with a reduced prevalence of heartburn. Prevention of ulcer relapse could be the true cause of this reduction.Keywords
This publication has 26 references indexed in Scilit:
- Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus ReportAlimentary Pharmacology & Therapeutics, 2002
- Symptomatic benefit 1-3 years after h. pylori eradication in ulcer patients: impact of gastroesophageal reflux diseaseAmerican Journal of Gastroenterology, 2000
- Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1999
- The GU‐MACH study: the effect of 1‐week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcerAlimentary Pharmacology & Therapeutics, 1999
- The DU‐MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapyAlimentary Pharmacology & Therapeutics, 1999
- Review article:Helicobacter pyloriand gastro‐oesophageal reflux disease—clinical implications and managementAlimentary Pharmacology & Therapeutics, 1999
- Helicobacter pylori Infection and Risk of Cardia Cancer and Non-Cardia Gastric Cancer: A Nested Case-Control StudyScandinavian Journal of Gastroenterology, 1999
- No increase of reflux symptoms or esophagitis in patients with non-ulcer dyspepsia 12 months after Helicobacter pylori eradication. A randomized double-blind placebo-controled trialGastroenterology, 1998
- Differing Patterns ofHelicobacter pyloriGastritis in Patients with Duodenal, Prepyloric, and Gastric Ulcer DiseaseScandinavian Journal of Gastroenterology, 1998
- Helicobacter pylori and acid secretion: where are we now?European Journal of Gastroenterology & Hepatology, 1997